The protective effect of lactoferrin on ventral mesencephalon neurons against MPP+ is not connected with its iron binding ability

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wang, Jun ^a   Bi, Mingxia ^a   Liu, Huiying ^a   Song, Ning ^a   Xie, Junxia ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; IRON; LACTOFERRIN; LACTOFERRIN RECEPTORS; MESSENGER RNA; NEUROPROTECTIVE AGENT; PROTEIN BAX; PROTEIN BCL 2; SUPEROXIDE DISMUTASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MESENCEPHALON; METABOLISM; MICROGLIA; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL; RAT;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CELLS, CULTURED; GENE EXPRESSION REGULATION; IRON; LACTOFERRIN; MEMBRANE POTENTIAL, MITOCHONDRIAL; MESENCEPHALON; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SUPEROXIDE DISMUTASE;

EID: 84934880850     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10729     Document Type: Article

References (39)

1. Zecca, L., Youdim, M. B., Riederer, P., Connor, J. R. & Crichton, R. R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 5, 863-873 (2004).
2. Kaur, D. et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 37, 899-909 (2003).
3. Johnson, E. E. & Wessling-Resnick, M. Iron metabolism and the innate immune response to infection. Microbes Infect. 14, 207-216 (2012).
4. Fillebeen, C. et al. Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res Mol Brain Res. 96, 103-113 (2001).
5. Faucheux, B. A. et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci USA 92, 9603-9607 (1995).
6. Brock, J. H. The physiology of lactoferrin. Biochem Cell Biol. 80, 1-6 (2002).
7. Rousseau, E., Michel, P. P. & Hirsch, E. C. The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis. Molecular pharmacology. 84, 888-898 (2013).
8. McCarthy, K. D. & de Vellis, J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 85, 890-902 (1980).
9. Suzumura, A., Mezitis, S. G., Gonatas, N. K. & Silberberg, D. H. MHC antigen expression on bulk isolated macrophage-microglia from newborn mouse brain: induction of Ia antigen expression by gamma-interferon. J Neuroimmunol. 15, 263-278 (1987).
10. Gao, H. M., Hong, J. S., Zhang, W. & Liu, B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 22, 782-790 (2002).
11. Liu, B., Du, L. & Hong, J. S. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther. 293, 607-617 (2000).
12. Zhang, S., Wang, J., Song, N., Xie, J. & Jiang, H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol Aging. 30, 1466-1476 (2009).
13. Song, N., Wang, J., Jiang, H. & Xie, J. Ferroportin1 and hephaestin overexpression attenuate iron-induced oxidative stress in MES23.5 dopaminergic cells. J Cell Biochem. 110, 1063-1072 (2010).
14. Hegde, N. V., Jensen, G. L. & Unger, E. L. Iron chelation down-regulates dopamine transporter expression by decreasing mRNA stability and increasing endocytosis in N2a cells. Exp Cell Res. 317, 405-412 (2011).
15. Prus, E. & Fibach, E. Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A. 73, 22-27 (2008).
16. Bratosin, D., Mitrofan, L., Palii, C., Estaquier, J. & Montreuil, J. Novel fluorescence assay using calcein-AM for the determination of human erythrocyte viability and aging. Cytometry A. 66, 78-84 (2005).
17. Liu, H. G. et al. Effect of Sevoflurane postconditioning on gene expression in brain tissue of the middle cerebral artery occlusion rat model. Mol Biol Rep. 39, 10505-10513 (2012).
18. Pape, M. et al. The long-term effect of sevoflurane on neuronal cell damage and expression of apoptotic factors after cerebral ischemia and reperfusion in rats. Anesth Analg. 103, 173-179, table of contents (2006).
19. McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38, 1285-1291 (1988).
20. Tanaka, S. et al. Activation of microglia induces symptoms of Parkinson's disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation. 10, 143 (2013).
21. Lull, M. E. & Block, M. L. Microglial activation and chronic neurodegeneration. Neurotherapeutics. 7, 354-365 (2010).
22. Sawada, H. et al. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci Res. 85, 1752-1761 (2007).
23. Zhang, X., Surguladze, N., Slagle-Webb, B., Cozzi, A. & Connor, J. R. Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia. 54, 795-804 (2006).
24. Baker, E. N. et al. Three-dimensional structure of lactoferrin in various functional states. Adv Exp Med Biol. 357, 1-12 (1994).
25. Davidson, L. A. & Lonnerdal, B. Fe-saturation and proteolysis of human lactoferrin: effect on brush-border receptor-mediated uptake of Fe and Mn. Am J Physiol. 257, G930-934 (1989).
26. Good, P. F., Olanow, C. W. & Perl, D. P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain research. 593, 343-346 (1992).
27. Jiang, R., Lopez, V., Kelleher, S. L. & Lonnerdal, B. Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. Journal of cellular physiology. 226, 3022-3031 (2011).
28. Willnow, T. E., Goldstein, J. L., Orth, K., Brown, M. S. & Herz, J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. The Journal of biological chemistry. 267, 26172-26180 (1992).
29. Yamamoto, K. et al. Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding. The Journal of biological chemistry. 289, 6462-6474 (2014).
30. Tooyama, I. et al. Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2-macroglobulin receptor) in human brain. Brain research. 691, 235-238 (1995).
31. Mehra, N. K., Mishra, V. & Jain, N. K. Receptor-based targeting of therapeutics. Therapeutic delivery. 4, 369-394 (2013).
32. Hu, K. et al. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. International journal of pharmaceutics. 415, 273-283 (2011).
33. Miao, D. et al. Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. Molecular pharmaceutics. 11, 90-101 (2014).
34. Poirier, J., Donaldson, J. & Barbeau, A. The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. Biochemical and biophysical research communications. 128, 25-33 (1985).
35. Yang, J., Su, Y. & Richmond, A. Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway. Free Radic Biol Med. 42, 1369-1380 (2007).
36. Noworyta-Sokolowska, K., Gorska, A. & Golembiowska, K. LPS-induced oxidative stress and inflammatory reaction in the rat striatum. Pharmacol Rep. 65, 863-869 (2013).
37. Kidd, P. M. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev. 5, 502-529 (2000).
38. Vila, M. et al. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem. 74, 721-729 (2000).
39. Lin, T. Y., Chiou, S. H., Chen, M. & Kuo, C. D. Human lactoferrin exerts bi-directional actions on PC12 cell survival via ERK1/2 pathway. Biochemical and biophysical research communications. 337, 330-336 (2005).